The mission of BioOnco, is a leading biotechnology company , to develop diagnostics , therapeutics and vaccines for diverse infectious diseases of both viral and bacterial origin and cancer. The genome based approach coupled with frontier genetic engineering methodologies make our products efficient, in-expensive and affordable. BioOnco is committed to enhancing the sustainability of enterprise through the optimal flow of innovative knowledge in research. BioOnco is located near Hyderabad, India. It has built a management team blending entrepreneurialism and industry experience and attracting investors & funds.BioOnco's Business model specifies four competitive strategies.
Emtech Bio is a partnership between Emory University and Georgia Institute of Technology. Founded in 2000, Emtech Biotechnology Development, Inc. offers laboratory space and use of scientific equipment to start-up and early-stage bioscience companies in a convenient location on Emory University's Briarcliff Campus in Atlanta, GA.
International Bio Recovery Corporation (IBR) has developed an environmental technology, which processes organic material from municipal solid waste, agricultural manures and surplus organics from food production into environmentally progressive fertility products. It has developed certain biotechnology processes to provide a waste conversion service to customers who must dispose of biodegradable waste. The process converts the waste into organic fertilizer products. The Company operates a plant in North Vancouver, British Columbia. It sells technology licenses to other users. It has a conversion facility in North Vancouver. The prime functions of the plant are to provide product for research and market development and to demonstrate operations to prospective technology and fertilizer buyers. (Source: ARS)
Aresa A/S is a Denmark-based company active in the plant biotechnology industry. It focuses on the BioSensor patent-protected technology. The activities connected with the BioSensor technology cover a controlled color change in plants, by use of such products as RedDetect, RedDetect UXO and RedScreen. The technology is based on the plant Arabidopsis thaliana (thale cress). The Company operates through two wholly owned subsidiaries, Aresa Biodetection ApS and Aresa BioPharma ApS. Aresa BioPharma ApS is a dormant company. Aresa A/S was founded in 2001 by Carsten Meier, and has its scientific outset from the Institute of Molecular Biology and Physiology, Copenhagen University, Denmark.
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases - from inflammatory diseases to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAiTM). The company's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. Cequent designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center, Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006 with seed funding from Ampersand Ventures, New England Partners, Novartis Option Fund and Pappas Ventures.
Indigene, a rapidly growing biopharmaceutical company, was founded in 2002 with a strategic focus to rapidly develop and deliver innovative, safe, and effective molecular combination based healthcare products. We call this unique offering Multiceutics. These molecular combinations are optimized to work simultaneously on multiple pathways associated with diseases and symptoms of the human body. This unique product development approach results in smarter medicines, as compared to the traditional Pharma industry approach of using a single molecule to target a single pathway among the network of multiple pathways that are associated with diseases and symptoms. We believe that Indigene is at the forefront of an emerging trend in the Pharmaceutical industry toward developing molecular combination based drugs. Combining our vision, passion, and commitment with our customer and product focused business model, we have made significant advances in developing our extensive knowledge base, proprietary multiplex molecular technology platform, new products, and a sustainable innovative product pipeline. Our immediate goal is to continue to leverage our core company strengths in the USA, Canada, Europe, and India; and to globally launch a series of unique products in both Consumer Healthcare (CHC) and Prescription Drug (Rx) markets. Ultimately, our end goal is to have Indigene recognized as a major market contributor in developing and delivering innovative and scientifically advanced products that seek to improve the overall health and quality of human life.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory